Literature DB >> 8629745

Use of peak expiratory flow rate in emergency department evaluation of acute exacerbation of chronic obstructive pulmonary disease.

C L Emerman1, R K Cydulka.   

Abstract

STUDY
OBJECTIVE: The purpose of the study was to compare peak expiratory flow rate (PEFR) against 1-second forced expiratory volume (FEV1) as a measure of airway obstruction in patients with acute exacerbation of chronic obstructive pulmonary disease (COPD).
METHODS: The participants were patients older than 50 years of age who presented with an acute exacerbation of COPD to the emergency department of a large, urban medical center. Pulmonary function was measured with a computerized Fleisch pneumotachygraphic spirometer before, during, and after treatment. PEFR and FEV1 were compared both as absolute values and after conversion to percent of predicted normal values (PPVs).
RESULTS: Five hundred fifty-six paired sets of measurements of FEV1 and PEFR were obtained from 199 patients and compared. There was good correlation between PEFR and FEV1, both in terms of absolute value (r=84; P<.001) and in terms of PPV (r=81; P<.001). Despite good correlation, further analysis revealed that there was not uniformly good agreement between the PPVs for FEV1 and PEFR. Although the mean difference between the PPVs obtained from the two measurements was only 4.3%, the 95% limits of agreement ranged widely, from -15% to 24%.
CONCLUSION: Although PEFR can be used as an alternative measure of airway obstruction in instances in which FEV1 is not available, there may be clinically significant discrepancies between the two tests. Measurement of the FEV1 is preferable because it allows comparison with baseline studies and previously published guidelines.

Entities:  

Mesh:

Year:  1996        PMID: 8629745     DOI: 10.1016/s0196-0644(96)70317-7

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  8 in total

Review 1.  COPD exacerbations.5: management.

Authors:  R Rodríguez-Roisin
Journal:  Thorax       Date:  2006-06       Impact factor: 9.139

Review 2.  Magnesium sulfate for acute exacerbations of chronic obstructive pulmonary disease.

Authors:  Han Ni; Swe Zin Aye; Cho Naing
Journal:  Cochrane Database Syst Rev       Date:  2022-05-26

3.  Can a normal peak expiratory flow exclude severe chronic obstructive pulmonary disease?

Authors:  R Perez-Padilla; W M Vollmer; J C Vázquez-García; P L Enright; A M B Menezes; A S Buist
Journal:  Int J Tuberc Lung Dis       Date:  2009-03       Impact factor: 2.373

4.  Spirometric correlates of dyspnea improvement among emergency department patients with chronic obstructive pulmonary disease exacerbation.

Authors:  Carlos A Camargo; Chu-Lin Tsai; Sunday Clark; Patrick A Kenney; Michael S Radeos
Journal:  Respir Care       Date:  2008-07       Impact factor: 2.258

5.  Peak expiratory flow rate underestimates severity of airflow obstruction in acute asthma.

Authors:  Inseon S Choi; Youngil I Koh; Ho Lim
Journal:  Korean J Intern Med       Date:  2002-09       Impact factor: 2.884

6.  Once Daily Versus Overnight and Symptom Versus Physiological Monitoring to Detect Exacerbations of Chronic Obstructive Pulmonary Disease: Pilot Randomized Controlled Trial.

Authors:  Ahmed M Al Rajeh; Yousef Saad Aldabayan; Abdulelah Aldhahir; Elisha Pickett; Shumonta Quaderi; Jaber S Alqahtani; Swapna Mandal; Marc Ci Lipman; John R Hurst
Journal:  JMIR Mhealth Uhealth       Date:  2020-11-13       Impact factor: 4.773

7.  Case-finding of chronic obstructive pulmonary disease with questionnaire, peak flow measurements and spirometry: a cross-sectional study.

Authors:  Bassam Mahboub; Ashraf Alzaabi; Joan B Soriano; Laila Salameh; Yousef A L Mutairi; Afzalhussein A Yusufali; Alawi Alsheikh-ali; Wael Almahmeed; John Haughney
Journal:  BMC Res Notes       Date:  2014-04-16

8.  The association between forced expiratory volume in one second (FEV1) and pulse oximetric measurements of arterial oxygen saturation (SpO2) in the patients with COPD: A preliminary study.

Authors:  Mohammad Emami Ardestani; Moloud Abbaszadeh
Journal:  J Res Med Sci       Date:  2014-03       Impact factor: 1.852

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.